Pure Global AI
NCT06210971Not yet recruiting

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Exploratory Study on the Efficacy and Safety of Long-course Neoadjuvant Chemoradiation With Liposomal Irinotecan and Capecitabine Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer
Hebei Medical University Fourth HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
liposomal irinotecan
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hebei Medical University Fourth Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Feb 01, 2024
End date
Jul 01, 2028
Enrollment
60 participants
Primary outcome

Pathologic Complete Response

Summary

This single-arm trial will explore the efficacy and safety of long-course neoadjuvant
 chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients
 with locally advanced rectal cancer.

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06210971
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06210971 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hebei Medical University Fourth Hospital and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.